Kynam Capital Management GP, LLC 4
Accession 0000919574-25-001923
Filed
Mar 12, 8:00 PM ET
Accepted
Mar 13, 6:18 PM ET
Size
16.6 KB
Accession
0000919574-25-001923
Insider Transaction Report
- Sale
Common Stock, par value $0.0001 per share
2025-03-11$4.93/sh−5,953,825$29,352,357→ 0 total(indirect: See Footnote) - Sale
Common Stock, par value $0.0001 per share
2025-03-11$4.93/sh−5,142,111$25,350,607→ 0 total - Sale
Common Stock, par value $0.0001 per share
2025-03-11$4.93/sh−5,142,111$25,350,607→ 0 total(indirect: See Footnote)
- Sale
Common Stock, par value $0.0001 per share
2025-03-11$4.93/sh−5,142,111$25,350,607→ 0 total - Sale
Common Stock, par value $0.0001 per share
2025-03-11$4.93/sh−5,142,111$25,350,607→ 0 total(indirect: See Footnote) - Sale
Common Stock, par value $0.0001 per share
2025-03-11$4.93/sh−5,953,825$29,352,357→ 0 total(indirect: See Footnote)
- Sale
Common Stock, par value $0.0001 per share
2025-03-11$4.93/sh−5,953,825$29,352,357→ 0 total(indirect: See Footnote) - Sale
Common Stock, par value $0.0001 per share
2025-03-11$4.93/sh−5,142,111$25,350,607→ 0 total - Sale
Common Stock, par value $0.0001 per share
2025-03-11$4.93/sh−5,142,111$25,350,607→ 0 total(indirect: See Footnote)
- Sale
Common Stock, par value $0.0001 per share
2025-03-11$4.93/sh−5,142,111$25,350,607→ 0 total - Sale
Common Stock, par value $0.0001 per share
2025-03-11$4.93/sh−5,953,825$29,352,357→ 0 total(indirect: See Footnote) - Sale
Common Stock, par value $0.0001 per share
2025-03-11$4.93/sh−5,142,111$25,350,607→ 0 total(indirect: See Footnote)
- Sale
Common Stock, par value $0.0001 per share
2025-03-11$4.93/sh−5,142,111$25,350,607→ 0 total - Sale
Common Stock, par value $0.0001 per share
2025-03-11$4.93/sh−5,953,825$29,352,357→ 0 total(indirect: See Footnote) - Sale
Common Stock, par value $0.0001 per share
2025-03-11$4.93/sh−5,142,111$25,350,607→ 0 total(indirect: See Footnote)
Footnotes (3)
- [F1]The reported securities are owned directly by Kynam Global Healthcare Master Fund, LP (the "Master Fund"), a private investment fund managed by Kynam Capital Management, LP (the "Adviser"), and separately managed account clients of the Adviser and may be deemed to be indirectly beneficially owned by (i) the Adviser, (ii) Kynam Capital Management GP, LLC (the "Adviser GP"), the general partner of the Adviser and (iii) Yue Tang, the managing member of the Adviser GP. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
- [F2]The reported securities are directly owned by the Master Fund. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
- [F3]The reported securities are owned directly by the Master Fund and may be deemed to be indirectly beneficially owned by Kynam Fund GP, LLC, the general partner of the Master Fund. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Documents
Issuer
2seventy bio, Inc.
CIK 0001860782
Related Parties
1- filerCIK 0001990033
Filing Metadata
- Form type
- 4
- Filed
- Mar 12, 8:00 PM ET
- Accepted
- Mar 13, 6:18 PM ET
- Size
- 16.6 KB